Literature DB >> 16238916

Intravesical therapy for overactive bladder.

Robert J Evans1.   

Abstract

Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic therapy. Despite the development of new antimuscarinic agents, many patients do not tolerate or fail to respond to oral therapy. Intravesical instillation therapy can provide an alternative method of managing bladder overactivity. Intravesical instillation of anticholinergics such as oxybutynin and atropine can achieve cholinergic blockade without producing systemic side effects. Botulinum A toxin injected directly into the detrusor has been shown in preliminary studies to increase bladder capacity and decrease uncontrolled bladder contractility for up to 6 months. Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers and when administered into the bladder, lead to an increase in functional bladder capacity. Intravesical capsaicin and resiniferatoxin also affect afferent innervation by blocking C-fiber afferents, leading to decreased bladder contractility and increased bladder capacity. Intravesical instillation therapy can provide an alternative treatment for the management of overactive bladder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238916     DOI: 10.1007/s11934-005-0037-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  45 in total

1.  Systemic effects of intravesical atropine sulphate.

Authors:  R Enskat; C N Deaney; S Glickman
Journal:  BJU Int       Date:  2001-05       Impact factor: 5.588

Review 2.  Intravesical therapy options for neurogenic detrusor overactivity.

Authors:  André Reitz; Brigitte Schurch
Journal:  Spinal Cord       Date:  2004-05       Impact factor: 2.772

3.  The effect of intravesical Marcain instillation on hyperreflexic detrusor contractions.

Authors:  P D McInerney; A Grant; J Chawla; T P Stephenson
Journal:  Paraplegia       Date:  1992-02

4.  The pharmacokinetics of intravesical and oral oxybutynin chloride.

Authors:  C A Massad; B A Kogan; F E Trigo-Rocha
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

5.  Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Robert L Stephen; Pierluigi Navarra; Giorgio Scivoletto; Ettore Mearini; Massimo Porena
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

6.  Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study.

Authors:  M Lazzeri; P Beneforti; M Spinelli; A Zanollo; G Barbagli; D Turini
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

7.  Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study.

Authors:  M Lazzeri; P Beneforti; G Benaim; C A Maggi; A Lecci; D Turini
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

Review 8.  Muscarinic receptor antagonists in the treatment of overactive bladder.

Authors:  C R Chapple
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

9.  The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.

Authors:  N G Kasabian; J D Vlachiotis; A Lais; B Klumpp; M D Kelly; M B Siroky; S B Bauer
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

Review 10.  Current and future pharmacological treatment for overactive bladder.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

View more
  3 in total

Review 1.  [Intravesical treatment of overactive bladder syndrome].

Authors:  A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Diagnosis of interstitial cystitis/ painful bladder syndrome in patients with overactive bladder symptoms.

Authors:  Scott A Macdiarmid; Peter K Sand
Journal:  Rev Urol       Date:  2007

3.  Treating acute cystitis with biodegradable micelle-encapsulated quercetin.

Authors:  Bi Lan Wang; Xiang Gao; Ke Men; Jinfeng Qiu; Bowen Yang; Ma Ling Gou; Mei Juan Huang; Ning Huang; Zhi Yong Qian; Xia Zhao; Yu Quan Wei
Journal:  Int J Nanomedicine       Date:  2012-05-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.